Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
200 eyes with each subtype of neovascular age-related macular degeneration will be included
in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual
acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT)
will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes
(group 1) were compared to the data of eyes that had undergone prior treatment with
photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).